FDA APPROVES TEVA'S GENERIC UNIRETIC

Teva Pharmaceutical Industries announced that the FDA has approved its abbreviated new drug application for moexipril HCl/hydrochlorothiazide tablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. The company said it would begin shipping the products immediately.

The drug is the first AB-rated generic equivalent of Schwarz Pharma's Uniretic, which is indicated for the treatment of hypertension, Teva said.

The brand product has annual sales of approximately $30 million in the U.S., according to Teva.